Fully implantable patient specific Artificial Hearts without External Power
Patient population with end-stage heart failure in the EU grows by 5M annually. Due to donor shortage, only a handful of patients ever receive cardiac transplantation. Unfortunately, this results in 250K deaths every year. Long-te...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Aeson®
The World’s Only Bioprosthetic Auto-regulated Artificial Hea...
12M€
Cerrado
fitsCAN
Blood flow induced thrombosis and stenosis due to cannulatio...
2M€
Cerrado
ArtOfHeart
The first Total Artificial Heart (TAH) that truly mimics the...
38M€
Cerrado
Contraband
ContraBand: the only heart failure medical device that is pl...
4M€
Cerrado
RTI2018-096320-B-C21
BIOINGENIERIA DE CONSTRUCTOS BASADOS EN BIOMATERIALES PARA L...
182K€
Cerrado
Información proyecto BloodTurbine
Duración del proyecto: 26 meses
Fecha Inicio: 2021-08-30
Fecha Fin: 2023-10-31
Líder del proyecto
KOC UNIVERSITY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Descripción del proyecto
Patient population with end-stage heart failure in the EU grows by 5M annually. Due to donor shortage, only a handful of patients ever receive cardiac transplantation. Unfortunately, this results in 250K deaths every year. Long-term mechanical circulatory support (MCS) is a solution, but external power needs result in driveline infections and bulky systems limiting patient mobility. An innovative blood turbine device emerged from the parent ERC that can overcome these limitations. This novel turbine can drive MCS by transferring the available cardiovascular energy to the diseased site without the need of external power. The proposed passive concept (at TRL 6-7) will realize the long-sought use of ventricle assist devices (VAD) as a destination therapy. PoC project will enable the timely translation of a disruptive device to the bedside, by completing device optimization, comparative analysis and key preclinical experiments in accordance with the new MDR regulatory framework. Business development, valuation and IPR activities are also budgeted. Elimination of the bulky power systems and control units allowed three-dimensional printing of this artificial heart from biocompatible resins. This resulted a new customized VAD concept that can be precisely tailored for each individual patient needs. Furthermore, the comparatively low product cost (€1K vs. €120K) will allow access to a major untapped global market reaching 18 million people annually, as many developing countries have no access to expensive MCS systems. These intriguing business opportunities will be validated, and major commercialization tasks will be completed through a strong team of business mentors, clinicians and cardiovascular device experts. In addition to the adults with right-heart failure, the developed device will improve the post-operative quality life of children with heart defects that require staged cardiovascular surgeries. Socioeconomic impacts span both the patients and their families.